{"id":1430,"date":"2019-09-09T09:00:00","date_gmt":"2019-09-09T09:00:00","guid":{"rendered":"https:\/\/lee-pharm.com\/zhaoke-guangzhou-oncology-pharmaceutical-ltd-had-a-very-successful-meeting-with-the-reviewers-from-the-center-for-drug-evaluation-of-nmpa-of-china\/"},"modified":"2026-09-24T10:22:19","modified_gmt":"2026-09-24T10:22:19","slug":"zhaoke-guangzhou-oncology-pharmaceutical-ltd-had-a-very-successful-meeting-with-the-reviewers-from-the-center-for-drug-evaluation-of-nmpa-of-china","status":"publish","type":"post","link":"https:\/\/lee-pharm.com\/en\/zhaoke-guangzhou-oncology-pharmaceutical-ltd-had-a-very-successful-meeting-with-the-reviewers-from-the-center-for-drug-evaluation-of-nmpa-of-china\/","title":{"rendered":"Zhaoke (Guangzhou) Oncology Pharmaceutical Ltd.had a very successful meeting with the reviewers from the Center for Drug Evaluation of NMPA of China"},"content":{"rendered":"<p>September 9, 2019, Zhaoke (Guangzhou) Oncology Pharmaceutical Ltd. had a very successful meeting with the reviewers from the Center for Drug Evaluation of NMPA of China. The purpose of the meeting was to discuss the planed combination trial of the new drugs, anti-PD-L1 monoclonal antibody and Oncolytic virus Pexa-vec.<\/p>\n<p class=\"lpns-download-wrap\"><a class=\"lpns-download\" href=\"https:\/\/www.leespharm.com\/wp-content\/uploads\/2019\/09\/Meeting-with-Centre-for-Drug-Evaluation-of-NMPA-of-China-Eng-version.pdf\" target=\"_blank\" rel=\"noopener\">\u0e14\u0e32\u0e27\u0e19\u0e4c\u0e42\u0e2b\u0e25\u0e14\u0e02\u0e48\u0e32\u0e27\u0e09\u0e1a\u0e31\u0e1a\u0e40\u0e15\u0e47\u0e21 (PDF)<\/a><\/p>\n<p><em>\u0e17\u0e35\u0e48\u0e21\u0e32: <a href=\"https:\/\/www.leespharm.com\/media\/?filter=Recent\" target=\"_blank\" rel=\"noopener\">Lee&#8217;s Pharmaceutical Holdings \u2013 News &amp; Media<\/a><\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>September 9, 2019, Zhaoke (Guangzhou) Oncology Pharmaceutical Ltd. had a very successful meeting with the reviewers from the Center for Drug Evaluation of NMPA of China. The purpose of the meeting was to discuss the planed combination trial of the new drugs, anti-PD-L1 monoclonal antibody and Oncolytic virus Pexa-vec. \u0e14\u0e32\u0e27\u0e19\u0e4c\u0e42\u0e2b\u0e25\u0e14\u0e02\u0e48\u0e32\u0e27\u0e09\u0e1a\u0e31\u0e1a\u0e40\u0e15\u0e47\u0e21 (PDF) \u0e17\u0e35\u0e48\u0e21\u0e32: Lee&#8217;s Pharmaceutical Holdings [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1431,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[32,29],"tags":[],"class_list":["post-1430","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-lees-pharm-group-news","category-news"],"_links":{"self":[{"href":"https:\/\/lee-pharm.com\/en\/wp-json\/wp\/v2\/posts\/1430","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lee-pharm.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lee-pharm.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lee-pharm.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lee-pharm.com\/en\/wp-json\/wp\/v2\/comments?post=1430"}],"version-history":[{"count":1,"href":"https:\/\/lee-pharm.com\/en\/wp-json\/wp\/v2\/posts\/1430\/revisions"}],"predecessor-version":[{"id":1432,"href":"https:\/\/lee-pharm.com\/en\/wp-json\/wp\/v2\/posts\/1430\/revisions\/1432"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lee-pharm.com\/en\/wp-json\/wp\/v2\/media\/1431"}],"wp:attachment":[{"href":"https:\/\/lee-pharm.com\/en\/wp-json\/wp\/v2\/media?parent=1430"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lee-pharm.com\/en\/wp-json\/wp\/v2\/categories?post=1430"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lee-pharm.com\/en\/wp-json\/wp\/v2\/tags?post=1430"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}